CA3228080A1 - Radioconjugues ciblant cd33 dans le traitement de cancers - Google Patents

Radioconjugues ciblant cd33 dans le traitement de cancers Download PDF

Info

Publication number
CA3228080A1
CA3228080A1 CA3228080A CA3228080A CA3228080A1 CA 3228080 A1 CA3228080 A1 CA 3228080A1 CA 3228080 A CA3228080 A CA 3228080A CA 3228080 A CA3228080 A CA 3228080A CA 3228080 A1 CA3228080 A1 CA 3228080A1
Authority
CA
Canada
Prior art keywords
radiolabeled
antibody
cancer
sarcoma
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3228080A
Other languages
English (en)
Inventor
Mary M. Chen
Avinash Desai
Dale L. Ludwig
Mark Berger
Sandesh SETH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinium Pharmaceuticals Inc
Original Assignee
Actinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/532,919 external-priority patent/US20220143228A1/en
Application filed by Actinium Pharmaceuticals Inc filed Critical Actinium Pharmaceuticals Inc
Publication of CA3228080A1 publication Critical patent/CA3228080A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des méthodes de traitement de cancers et de troubles prolifératifs, tels que des cancers à tumeur solide et des tumeurs malignes hématologiques non myéloïdes, à l'aide de radioconjugués ciblant CD33, seuls ou en combinaison avec un ou plusieurs radioconjugués ciblant d'autres cibles associées au cancer telles que DR5, 5T4, HER3 et TROP2, des conjugués anticorps-médicament ciblant ces cibles ou d'autres cibles associées au cancer, des anticorps thérapeutiques ciblant ces cibles associées au cancer ou d'autres cibles associées au cancer, des agents et des régimes chimiothérapeutiques, ainsi que des inhibiteurs de point de contrôle immunitaire.
CA3228080A 2021-08-06 2022-08-26 Radioconjugues ciblant cd33 dans le traitement de cancers Pending CA3228080A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163230431P 2021-08-06 2021-08-06
US17/532,919 US20220143228A1 (en) 2020-10-22 2021-11-22 Her3 radioimmunotherapy for the treatment of solid cancers
US17/532,919 2021-11-22
PCT/US2022/075506 WO2023015322A1 (fr) 2021-08-06 2022-08-26 Radioconjugués ciblant cd33 dans le traitement de cancers

Publications (1)

Publication Number Publication Date
CA3228080A1 true CA3228080A1 (fr) 2023-02-09

Family

ID=85156367

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3228080A Pending CA3228080A1 (fr) 2021-08-06 2022-08-26 Radioconjugues ciblant cd33 dans le traitement de cancers

Country Status (3)

Country Link
EP (1) EP4380632A1 (fr)
CA (1) CA3228080A1 (fr)
WO (1) WO2023015322A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024283114A1 (en) * 2023-06-01 2026-01-22 Actinium Pharmaceuticals, Inc. Combination therapies for the treatment of cd33-positive hematological malignancies harboring mutations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187074A1 (fr) * 2017-04-03 2018-10-11 Immunomedics, Inc. Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse
EP3755348A4 (fr) * 2018-02-20 2022-03-02 Dragonfly Therapeutics, Inc. Domaines variables d'anticorps ciblant cd33, et leur utilisation
EP3849565A4 (fr) * 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center Réduction de l'expression de cd33 pour protéger sélectivement des cellules thérapeutiques
US20220288244A1 (en) * 2020-10-22 2022-09-15 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer

Also Published As

Publication number Publication date
EP4380632A1 (fr) 2024-06-12
WO2023015322A1 (fr) 2023-02-09

Similar Documents

Publication Publication Date Title
US20220211886A1 (en) Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
US20260053963A1 (en) Radioconjugates targeting cd33 in the treatment of breast cancer
US20230248855A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
US20220143228A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
US20240216554A1 (en) Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer
CA3123873A1 (fr) Radioimmunotherapie combinee et therapie de point de controle immunitaire dans le traitement du cancer
US20220288244A1 (en) Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
US20250339571A1 (en) Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
US12539340B2 (en) Radioconjugates targeting CD33 in the treatment of cancers
CA3228080A1 (fr) Radioconjugues ciblant cd33 dans le traitement de cancers
US20220251239A1 (en) Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
CA3227223A1 (fr) Combinaison de radioimmunotherapie et de blocage de cd47 dans le traitement du cancer
CA3199259A1 (fr) Radioimmunotherapie de her3 pour le traitement de cancers solides
US12551584B1 (en) Lewis Y radioimmunotherapy for the treatment of cancer
US20250205375A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
US20240226345A1 (en) Radioimmunoconjugates targeting calreticulin for use in the treatment of cancer
US20240390532A1 (en) Radioimmunoconjugates targeting grp78 for use in the treatment of cancer
CA3192391A1 (fr) Radioimmunotherapie de la glycoproteine trophoblastique pour le traitement de cancers solides
EP4637821A1 (fr) Radioimmunothérapie de her3 pour le traitement de cancers solides

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250822